Novel targeted therapies for R/R marginal zone lymphoma

It has been challenging to define an optimal therapeutic approach for relapsed patients with marginal zone lymphoma (MZL) due to disease...

Preliminary results from phase I studies of CD20 × CD3 bispecific antibodies in R/R B-cell non-Hodgkin lymphoma

For patients with B-cell non-Hodgkin lymphoma (NHL) who relapse or become refractory to...

Educational theme: CSF analysis of ctDNA for lymphoma with CNS involvement

This article is part of our educational series on the role of circulating tumor DNA (ctDNA) in the management of patients...

BL-IPI to support risk stratification and targeted novel treatment approaches for Burkitt lymphoma

Burkitt lymphoma (BL) is a highly aggressive B-cell non-Hodgkin lymphoma. BL is curable for most...

Satellite Symposium | Patient with R/R CLL—Latin American perspective

The virtual Lymphoma Hub Satellite Symposium, at the European School of Haematology (ESH) ‘2nd How to Diagnose and Treat:...

Satellite Symposium | Patient with R/R CLL—European perspective

The virtual Lymphoma Hub Satellite Symposium, at this year's European School of Haematology (ESH) ‘2nd How to Diagnose and Treat:...

Satellite Symposium | Patient with R/R DLBCL—European perspective

At this year’s European School of Haematology (ESH) ‘2nd How to Diagnose and Treat: Lymphoma’ conference, the Lymphoma Hub hosted a...

Satellite Symposium | Patient with R/R DLBCL—US perspective

At this year’s European School of Haematology (ESH) ‘2nd How to Diagnose and Treat: Lymphoma’ conference, the Lymphoma Hub was proud to host...

FDA biologics license application of ublituximab plus umbralisib for the treatment of CLL

On March 29, 2021, it was announced that a biologics license application (BLA) was submitted to the U.S. Food...

Phase II study of lenalidomide and R-CHOP in patients with diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) is recognized to be a molecularly heterogenous malignancy. Of the three...

Educational theme: 5hmC profiles of cfDNA predict R-CHOP treatment response in patients with DLBCL

This article is part of our educational series on the role of circulating tumor DNA (ctDNA) in the...

Updated ESMO guidelines for diagnosis, treatment, and follow-up of newly diagnosed and relapsed follicular lymphoma

In November 2020, the European Society for Medical Oncology (ESMO) Guidelines...